Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...
Educated Patient® MPN Summit Defining Essential Thrombocythemia Risk Presentation: November 19, 2022
Understanding the different types of risks faced by people with essential thrombocythemia, a type of cancer associated with uncontrolled growth of blood platelets, is crucial to helping patients live ...
Investor's Business Daily on MSN
Incyte gets FDA breakthrough therapy fast track for rare blood cancer drug
The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs.
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...
Inflammatory molecules circulating in the blood may worsen disease symptoms and points to new opportunities for targeted therapy.
Some of the main goals of treatments for essential thrombocythemia include reducing disease progression and blood clots while improving symptom burden, but more treatments may be on the horizon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback